Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGCD516 in Advanced Solid Tumor Malignancies
NCT02219711Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Aug 2014
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sitravatinib in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 2 more, sponsored by Mirati Therapeutics. Primary endpoints: Type of dose limiting adverse event, Area under the plasma concentration versus time curve up to 72 hours and 1 more. Started Aug 2014; status: completed.
02
Drugs
sitravatinib
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)clear cell renal cell carcinoma (ccRCC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02219711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219711.